# ⚕️ Comorbidity Management

## 🔄 Paradigm Shift: CKM Syndrome

Hypertension is no longer viewed as an isolated condition but as a key component of **Cardiovascular-Kidney-Metabolic (CKM) Syndrome**, requiring integrated, comprehensive management strategies that address all interconnected pathways.

### 🧬 Cardiovascular-Kidney-Metabolic Syndrome

#### 🫀 Cardiovascular Component

- Hypertension (primary or secondary)
- Coronary artery disease
- Heart failure (HFrEF, HFpEF)
- Atherosclerotic CVD

#### 🫘 Kidney Component

- CKD (any stage with albuminuria)
- Acute kidney injury
- Proteinuria/albuminuria
- Renovascular disease

#### 🍯 Metabolic Component

- Type 2 diabetes mellitus
- Prediabetes/insulin resistance
- Obesity (especially visceral)
- Metabolic syndrome

#### 🔗 Shared Mechanisms

- Insulin resistance
- Chronic inflammation
- Oxidative stress
- RAAS activation

### 🍯 Diabetes & Hypertension

#### 2025 Key Updates

**Class 1 Recommendation:** RAAS inhibition for *any* albuminuria (including \<30 mg/g previously considered normal)

#### Blood Pressure Targets

- **Standard:** \<130/80 mmHg
- **With CKD:** \<130/80 mmHg (unified target)
- **Avoid:** J-curve phenomenon \<120 mmHg

#### First-Line Agents

- **ACE inhibitor or ARB:** Mandatory for albuminuria
- **Diuretic:** Thiazide-type preferred
- **CCB:** Amlodipine or long-acting DHP
- **Avoid:** Beta-blockers unless specific indication

#### Novel Therapies

- **GLP-1 RA:** 3-5 mmHg reduction + weight loss
- **SGLT2i:** 4-6 mmHg reduction + cardio-renal protection
- **Finerenone:** Non-steroidal MRA for CKD + T2DM

### 🫘 Chronic Kidney Disease

#### 2025 Unified Approach

**Simplified Target:** \<130 mmHg systolic across ALL CKD stages (eliminates previous stage-specific targets)

#### RAAS Inhibition Protocol

- **Mandatory:** Albuminuria ≥30 mg/g
- **Acceptable:** 30% creatinine increase
- **Monitoring:** K+ and creatinine at 1-2 weeks
- **Discontinue:** K+ \>5.5 mEq/L or Cr increase \>50%

#### CKD Stage Considerations

- **Stage 1-2:** Aggressive BP control, lifestyle
- **Stage 3:** Monitor medication dosing, bone disease
- **Stage 4:** Nephrology referral, avoid K+-sparing
- **Stage 5:** Dialysis planning, volume management

#### Advanced Therapy Integration

- **SGLT2i:** eGFR ≥20 mL/min/1.73m² + proteinuria
- **Finerenone:** Alternative to spironolactone
- **Loop diuretics:** Stage 4-5 for volume control

### ❤️ Cardiovascular Disease

#### Intensive Targets (SPRINT Evidence)

**Target \<120 mmHg** when tolerated: 25% ↓ CV events, 27% ↓ mortality

#### Condition-Specific Targets

- **CAD:** \<130/80 mmHg, consider \<120 mmHg SBP
- **Heart Failure:** \<130/80 mmHg, ACE/ARB + BB
- **Stroke (chronic):** \<130/80 mmHg for prevention
- **PAD:** \<130/80 mmHg, avoid beta-blockers

#### Drug Selection Priorities

- **Post-MI:** ACE/ARB + beta-blocker mandatory
- **HFrEF:** ACE/ARB + BB + MRA + SGLT2i
- **HFpEF:** SGLT2i, ARB, MRA if appropriate
- **Stable CAD:** ACE/ARB + BB, avoid CCB if HF

#### Contraindications & Cautions

- **Avoid:** Non-DHP CCB in heart failure
- **Caution:** Beta-blockers in PAD (relative)
- **Monitor:** Orthostatic hypotension with intensive targets

### 🔗 Integration Strategies

#### Polypill Approach

**Single-pill combinations** improve adherence by 20-25% vs. multiple tablets

#### Recommended Combinations

- **ACE/ARB + CCB:** Most common, well-tolerated
- **ACE/ARB + HCTZ:** Cost-effective option
- **CCB + HCTZ:** Alternative if RAAS intolerant
- **Triple therapy:** ACE/ARB + CCB + diuretic

#### Sequential Addition Protocol

- **Step 1:** Dual combination (Stage 2 HTN)
- **Step 2:** Triple combination if not at goal
- **Step 3:** Spironolactone (resistant HTN)
- **Step 4:** Consider secondary causes, device therapy

#### Quality Metrics

- **Control Rate:** \<130/80 mmHg in comorbid patients
- **Medication Adherence:** \>80% using pharmacy records
- **Laboratory Monitoring:** K+, Cr q3-6 months

### 🔄 Integrated Treatment Pathway

#### 1️⃣ Assessment

PREVENT calculator\
Comorbidity screening\
Target organ damage

#### 2️⃣ Risk Stratification

CKM syndrome staging\
Intensive vs standard\
Special populations

#### 3️⃣ Drug Selection

Comorbidity-guided\
Single-pill combinations\
Novel therapies

#### 4️⃣ Monitoring

Home BP monitoring\
Lab surveillance\
Adherence assessment

#### 5️⃣ Optimization

Titration to goal\
Side effect management\
Specialist referral

### 💊 Comorbidity-Based Medication Matrix

| Medication Class | Diabetes | CKD | CAD | Heart Failure | Stroke | Special Benefits |
|----|----|----|----|----|----|----|
| **ACE Inhibitors** | High | High | High | High | Moderate | Renoprotection, post-MI |
| **ARBs** | High | High | Moderate | High | High | ACE inhibitor alternative |
| **CCBs (DHP)** | Moderate | Moderate | Moderate | Low | High | Stroke prevention, elderly |
| **Thiazide Diuretics** | Moderate | Moderate | Moderate | Moderate | High | Cost-effective, combinations |
| **Beta-blockers** | Low | Low | High | High | Low | Post-MI, HF mortality |
| **MRAs** | Moderate | Moderate | Moderate | High | Low | Resistant HTN, HF |
| **SGLT2 Inhibitors** | High | High | Moderate | High | Low | Cardiorenal protection |
| **GLP-1 RAs** | High | Moderate | Moderate | Low | Low | Weight loss, CV outcomes |

■ High Benefit \| ■ Moderate Benefit \| ■ Low Benefit \| ■ Contraindicated

### 🧮 Comorbidity Risk Calculator

#### Patient Characteristics

Age Systolic BP (mmHg) Diastolic BP (mmHg) Comorbidities Type 2 Diabetes Chronic Kidney Disease Coronary Artery Disease Heart Failure Albuminuria (mg/g)

#### CKM Risk Assessment

#### Medication Optimizer

Select patient comorbidities to get personalized medication recommendations based on 2025 guidelines.

Diabetes CKD CAD Heart Failure

#### Personalized BP Target Calculator

Calculate individualized blood pressure targets based on patient characteristics and comorbidities.

Age Group Cardiovascular Risk Tolerance to Intensive Therapy

### 🚀 Novel Integrated Therapies

#### 💉 GLP-1 Receptor Agonists

**BP Effect:** 3-5 mmHg reduction

**Additional Benefits:** Weight loss, CV outcomes

**Indication:** T2DM + HTN, obesity

**Evidence:** LEADER, SUSTAIN-6 trials

#### 🫘 SGLT2 Inhibitors

**BP Effect:** 4-6 mmHg reduction

**Additional Benefits:** Renoprotection, HF outcomes

**Indication:** T2DM, CKD, HF

**Evidence:** DAPA-HF, CREDENCE trials

#### ⚗️ Finerenone (Non-steroidal MRA)

**BP Effect:** 2-4 mmHg reduction

**Additional Benefits:** Lower hyperkalemia risk

**Indication:** T2DM + CKD

**Evidence:** FIDELIO-DKD, FIGARO-DKD

### 📅 Comprehensive Monitoring Timeline

Week 1-2

#### Initial Assessment & Drug Initiation

Baseline labs (K+, Cr, eGFR, albuminuria), medication counseling, home BP monitoring setup

Week 2-4

#### Early Monitoring & Adjustment

Repeat K+ and creatinine, assess for side effects, titrate medications if needed

Month 2-3

#### Target Assessment & Optimization

Evaluate BP control, add second/third agents, assess adherence, lifestyle counseling

Month 6

#### Comprehensive Review

Complete metabolic panel, HbA1c (if diabetic), albuminuria, complication screening

Ongoing

#### Long-term Management

Quarterly visits, annual comprehensive assessment, specialist referrals as needed

## 📚 Sources

1.  **Whelton PK, Carey RM, Aronow WS, et al.** 2017 ACC/AHA Guideline for High Blood Pressure in Adults. *Hypertension.* 2018;71(6):e13-e115. [PMID: 29133356](https://pubmed.ncbi.nlm.nih.gov/29133356/). \[Source for: comorbidity-specific BP targets and pharmacotherapy preferences (DM, CKD, HF, post-MI, stroke).\]
2.  **Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD.** Dapagliflozin in patients with chronic kidney disease. *N Engl J Med.* 2020;383(15):1436-1446. [PMID: 32970396](https://pubmed.ncbi.nlm.nih.gov/32970396/). \[Source for: SGLT2i renoprotection across CKD with and without diabetes; HR 0.61 primary composite.\]
3.  **EMPA-KIDNEY Collaborative Group.** Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2023;388(2):117-127. [PMID: 36331190](https://pubmed.ncbi.nlm.nih.gov/36331190/). \[Source for: empagliflozin in CKD across spectrum of eGFR 20-90 and albuminuria; HR 0.72 primary composite.\]
4.  **Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD.** Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med.* 2020;383(23):2219-2229. [PMID: 33264825](https://pubmed.ncbi.nlm.nih.gov/33264825/). \[Source for: finerenone CKD outcome benefit in T2D.\]
5.  **McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF.** Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med.* 2019;381(21):1995-2008. [PMID: 31535829](https://pubmed.ncbi.nlm.nih.gov/31535829/). \[Source for: SGLT2i in HFrEF — primary composite HR 0.74.\]
6.  **McMurray JJV, Packer M, Desai AS, et al; PARADIGM-HF.** Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. *N Engl J Med.* 2014;371(11):993-1004. [PMID: 25176015](https://pubmed.ncbi.nlm.nih.gov/25176015/). \[Source for: ARNI in HFrEF — primary HR 0.80.\]
7.  **PROGRESS Collaborative Group.** Randomised trial of a perindopril-based BP regimen among 6,105 individuals with previous stroke or TIA. *Lancet.* 2001;358(9287):1033-1041. [PMID: 11589932](https://pubmed.ncbi.nlm.nih.gov/11589932/). \[Source for: post-stroke BP-lowering for secondary prevention — stroke RRR 28%.\]

### 🎯 Key Learning Points

#### 🔬 CKM Syndrome Integration

- Hypertension as component of broader syndrome
- Shared pathophysiology requires unified approach
- Novel therapies provide multi-organ benefits

#### 🎯 Unified Targets

- \<130/80 mmHg across most comorbidities
- Consider \<120 mmHg SBP if tolerated
- RAAS inhibition for any albuminuria

#### 💊 Precision Medicine

- Comorbidity-guided drug selection
- Single-pill combinations for adherence
- SGLT2i and GLP-1 RA integration

#### 📊 Quality Metrics

- Control rates over treatment rates
- Medication adherence monitoring
- Comprehensive outcome tracking


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/comorbidity-management.html) · Markdown synchronized October 3, 2026.